The Pharmacology of Covid- 19


Severe acute respiratory syndrome corona virus 2 ( SARS ‐ CoV ‐ 2) is the cause of the original corona virus bug 2019 (COVID ‐ 19), a considerably pathogenic and sometimes fatal respiratory bug responsible for the current 2020 global plague. Non ‐ steroidal anti ‐ incendiary medications (NSAIDs) are medicaments really universally used to ease fever, pain, and inflammation (common symptoms of COVID ‐ 19 cases) through effectively blocking handiwork of prostaglandins (PGs) via inhibition of cyclooxyganase enzymes. PGs can exercise either proinflammatory or anti ‐ incendiary gear depending on the incendiary screenplay.



 


  • A hypothesis for pathobiology and treatment of COVID‐19: The centrality of ACE1/ACE2 imbalance
  • Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19
  • 3 PGs IN THE HUMAN LUNG
  • POSSIBLE IMMUNOPATHOLOGICAL MECHANISMS
  • Potential effects of clinical interventions of COVID‐19 on PG biosynthesis

Related Conference of The Pharmacology of Covid- 19

August 27-28, 2026

22nd Global Biomarkers and Clinical Research Summit

Paris, France
September 14-15, 2026

7th Global Summit on Digital Therapeutics

Barcelona, Spain
September 28-29, 2026

13th International Conference on Stroke and Neurological Disorders

Amsterdam, Netherlands
October 19-20, 2026

6th Euro-Global Summit on Probiotics & Nutraceuticals

Paris, France
November 16-17, 2026

11th Global Summit on Midwifery and Womens Health

Tokyo, Japan
December 16-17, 2026

7th Global Summit on Public Health

Amsterdam, Netherlands
January 18-19, 2027

44th International Conference on Women's Health

Bangkok, Thailand
January 18-19, 2027

10th World Congress on PCOS and Reproductive Healthcare

Bangkok, Thailand
February 01-02, 2027

9th International Conference on Digital Health

London, UK
May 17-18, 2027

38th European Heart and Heart Failure Congress

Paris, France

The Pharmacology of Covid- 19 Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in